Greater China was Usana Health Sciences’s largest region in fiscal 2026, bringing in $424.54M of $925.26M (46%).
| Geography | FY 2011 | FY 2011 | FY 2012 | FY 2013 | FY 2015 | FY 2016 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greater China | $475.10M | $457.98M | $424.54M | |||||||||||||
| North America/Europe | — | — | — | |||||||||||||
| Americas & Europe | $180.58M | $171.52M | $298.09M | |||||||||||||
| Southeast Asia Pacific | $163.89M | $146.80M | $132.00M | |||||||||||||
| Southeast Asia/Pacific | — | — | — | |||||||||||||
| North Asia | $101.45M | $78.21M | $70.63M | |||||||||||||
| Total | $921.01M | $854.50M | $925.26M |
Usana Health Sciences brought in $925.26M from its four regions in fiscal 2026, the year ended January 3, 2026. That was up 8.3% from $854.50M in fiscal 2024, the previous year with figures. Greater China was the largest at $424.54M (45.9%), ahead of Americas & Europe at $298.09M (32.2%) and Southeast Asia Pacific at $132.00M (14.3%). The remaining region, North Asia, brought in $70.63M.
Compared with fiscal 2024, the previous year with figures, Americas & Europe grew fastest, up 73.8% to $298.09M, while Southeast Asia Pacific fell the most, down 10.1% to $132.00M. From fiscal 2023 to 2026, combined revenue from these regions grew from $921.01M to $925.26M, a compound annual growth rate of 0.2%. Greater China's share of the total fell from 51.6% to 45.9%.
Core Nutritional was Usana Health Sciences’s largest segment in fiscal 2026, bringing in $775.45M of $925.26M (84%).
| Segment | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2026 |
|---|---|---|---|---|---|---|
| Direct Selling | — | — | — | |||
| Direct-Selling | — | — | — | |||
| Core Nutritional | $915.21M | $845.79M | $775.45M | |||
| Hiya Direct-To-Consumer | — | $1.97M | $131.97M | |||
| Other | $5.80M | $6.74M | $17.83M | |||
| All Other | — | — | — | |||
| Total | $921.01M | $854.50M | $925.26M |
Usana Health Sciences brought in $925.26M from its three segments in fiscal 2026, the year ended January 3, 2026. That was up 8.3% from $854.50M in fiscal 2024, the previous year with figures. Core Nutritional was the largest at $775.45M (83.8%), ahead of Hiya Direct-To-Consumer at $131.97M (14.3%) and Other at $17.83M (1.9%).
Compared with fiscal 2024, the previous year with figures, Hiya Direct-To-Consumer grew 6,599.0% to $131.97M, while Core Nutritional fell 8.3% to $775.45M.
Usana Health Sciences began breaking out Hiya Direct-To-Consumer in fiscal 2024, when it brought in $1.97M.
Usana Health Sciences (USNA) reports its revenue by geography and by segment. In fiscal 2026, Greater China was its largest region, bringing in $424.54M (45.9% of the total), followed by Americas & Europe at $298.09M (32.2%).
Greater China was Usana Health Sciences' largest region in fiscal 2026, bringing in $424.54M, or 45.9% of the $925.26M total across its four regions.
Core Nutritional was Usana Health Sciences' largest segment in fiscal 2026, bringing in $775.45M, or 83.8% of the $925.26M total across its three segments.
Every figure comes from Usana Health Sciences' annual financial filings, as reported. Each line keeps the name Usana Health Sciences gives it, and years follow its fiscal calendar.
Usana Health Sciences' revenue by geography goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.